News on clinical chemistry systems and applications.
The firm booked $484 million in revenues for Alere rapid diagnostics in the quarter, led by sales for infectious disease and cardiometabolic testing.
The newly independent firm will continue to invest in diagnostics by bringing its menu of PCR tests for infectious diseases to the US and other markets, among other objectives.
Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.